Blood thinner duration trial aims to save limbs in severe artery disease

NCT ID NCT07512960

Recruiting now Disease control Sponsor: Fondation Hôpital Saint-Joseph Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking two blood thinners (aspirin and clopidogrel) for 12 months after leg artery surgery is better than taking them for just 1 month in people with severe leg artery disease. The goal is to see if longer treatment prevents amputations or death. About 614 participants will be randomly assigned to either continue clopidogrel or switch to a placebo after the first month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clopidogrel
What this could lead to: If successful, this could establish the optimal duration of dual anti-platelet therapy to prevent amputations and deaths in people with severe leg artery disease.
What could go wrong: This is a phase 3 trial, but the optimal therapy duration is still debated. Results may not apply to all patients, and there is a risk of bleeding with longer anti-platelet use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIMB-THREATENING ISCHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

limb ischemia thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLTI DEFINED AS RUTHERFORD CATEGORY 4 OR 5

Contacts and locations

Locations

Hospital Saint Joseph
RECRUITING

Paris, Île-de-France Region, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.